IMMULITE® 2000 Systems OV OM-MA (CA125) 10380972Recalls & reported problems
Siemens Healthcare Diagnostics Products Ltd · CA 125 - IMMULITE - RGT - 200 Tests · Class 2
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 00630414961798), received between Aug 9, 2022 and Mar 24, 2026 — classified as 2 malfunctions.
The most frequently reported specific device problem is “High Test Results” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Reports received per month
Most reported problems
Device problems
- High Test Results1
- Low Test Results1
Patient problems
- No Clinical Signs, Symptoms or Conditions2
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
MalfunctionMar 24, 2026High Test Results
THE CUSTOMER REPORTED THE OBSERVATION OF A DISCORDANT ELEVATED OM-MA (OV) PATIENT RESULT WHEN USING KIT LOT 321 ON AN IMMULITE 2000 XPI INSTRUMENT. THE INITIAL RESULT WAS REPORTED TO AND QUESTIONED BY THE PHYSICIAN(S). THE SAMPLE WAS REPEATED ON THE INITIAL INSTRUMENT, AND THE REPEAT RESULT WAS LOWER, AND REPORTED AS THE CORRECT RESULT, TO THE PHYSICIAN(S). THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO THIS ISSUE.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24681026 ↗MalfunctionAug 9, 2022Low Test Results; Low Test Results
THE CUSTOMER OBSERVED DEPRESSED IMMULITE 2000 XPI OM-MA (CA125) DILUTED RESULTS FOR A PATIENT SAMPLE COMPARED TO REPEAT DILUTED RESULTS USING THE SAME INSTRUMENT. THE INITIAL RESULT READ ABOVE ASSAY MEASURING RANGE (500 U/ML) AND ONBOARD DILUTIONS WERE PERFORMED THREE TIMES WITH THE SAME SAMPLE. DISCORDANT LOW RESULTS WERE OBSERVED WITH THE FIRST SET OF DILUTED SAMPLE RESULTS. THE INITIAL DILUTED RESULTS WERE NOT REPORTED TO THE PHYSICIAN(S). THERE ARE NO REPORTS THAT TREATMENT WAS ALTERED OR PRESCRIBED OR ADVERSE HEALTH CONSEQUENCES DUE TO THE DISCORDANT IMMULITE 2000 XPI OM-MA (CA125) RESULTS.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 15195580 ↗
Other TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125) devices
- ADVIA Centaur® CA 125II 10310443Siemens Healthcare Diagnostics Inc. · TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125)1 recall10 reports
- ADVIA Centaur® CA 125 II 10315696Siemens Healthcare Diagnostics Inc. · TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125)1 recall0 reports
- ARCHITECT 02K4529Abbott GmbH · TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125)8 reports
- Atellica IM CA 125II 10995482Siemens Healthcare Diagnostics Inc. · TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125)3 reports
- ARCHITECT 02K4539Abbott GmbH · TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125)3 reports
- Alinity 08P4920Abbott GmbH · TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125)2 reports
- Alinity 08P4930Abbott GmbH · TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125)2 reports
- Elecsys CA 125 II Assay 11776223161Roche Diagnostics GmbH · TEST, EPITHELIAL OVARIAN TUMOR-ASSOCIATED ANTIGEN (CA125)2 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page